A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — ...

Following the onset of nonarteritic anterior ischemic optic neuropathy, regular stroke workup may be necessary.

MONDAY, Feb. 10, 2025 (HealthDay News) -- Yes, rare cases of vision issues have arisen in people taking popular GLP-1 weight ...

Get Instant Summarized Text (Gist) Once-weekly semaglutide use in individuals with type 2 diabetes more than doubles the risk of developing nonarteritic anterior ischemic optic neuropathy (NAION ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy in those with type 2 diabetes.

A retrospective case series identified nine patients who developed ophthalmic complications during treatment with semaglutide ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...

Popular GLP-1 medications like semaglutide and tirzepatide have been linked to rare vision issues, including NAION, raising ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

A small percentage have had vision problems, but a direct causal link with the drugs has not been established.